Middle East & Africa Vaccine Market Size & Outlook
- Pharmaceuticals
- Vaccines
- Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the vaccine market
MEA vaccine market highlights
- The MEA vaccine market generated a revenue of USD 2,730.1 million in 2025.
- The market is expected to grow at a CAGR of 4.7% from 2026 to 2033.
- In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
- Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
- Country-wise, Kuwait is expected to register the highest CAGR from 2026 to 2033.
MEA data book summary
| Market revenue in 2025 | USD 2,730.1 million |
| Market revenue in 2033 | USD 4,017.2 million |
| Growth rate | 4.7% (CAGR from 2026 to 2033) |
| Largest segment | Viral vaccines |
| Fastest growing segment | Other Indication |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.8% of the global vaccine market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 29,451.4 million by 2033.
Major markets in the MEA region include South Africa, Saudi Arabia, the UAE, and Kuwait. Economic development witnessed in emerging markets, such as South Africa, highly unmet healthcare needs, and high prevalence of diseases are some of the primary drivers of the market. Moreover, the increased prevalence of flu and the risk of seasonal influenza are propelling the market growth in the region.
Influenza vaccination can help prevent influenza-related illness, even in people who are at high risk of developing severe complications from the virus. This propelled many organizations, such as WHO, the Agency of Preventive Medicine, and Ministry of Health in Africa, to collaborate for monitoring & evaluating the occurrence of influenza among the population and initiate vaccination programs in the region.
In addition, an increase in government initiatives and a rise in partnerships between key players and healthcare providers are anticipated to boost the market over the forecast period. Furthermore, the increased death rate due to influenza infection is driving the need for the development of vaccines to prevent such conditions.
No credit card required*
Publish Date: Jul 28, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
Middle East & Africa Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 64.88% in 2025.
Horizon Databook has segmented the Middle East & Africa vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
Major markets in the MEA region include South Africa, Saudi Arabia, the UAE, and Kuwait. Economic development witnessed in emerging markets, such as South Africa, highly unmet healthcare needs, and high prevalence of diseases are some of the primary drivers of the market. Moreover, the increased prevalence of flu and the risk of seasonal influenza are propelling the market growth in the region.
Influenza vaccination can help prevent influenza-related illness, even in people who are at high risk of developing severe complications from the virus. This propelled many organizations, such as WHO, the Agency of Preventive Medicine, and Ministry of Health in Africa, to collaborate for monitoring & evaluating the occurrence of influenza among the population and initiate vaccination programs in the region.
In addition, an increase in government initiatives and a rise in partnerships between key players and healthcare providers are anticipated to boost the market over the forecast period. Furthermore, the increased death rate due to influenza infection is driving the need for the development of vaccines to prevent such conditions.
- Middle East & Africa Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Viral Vaccines
- Bacterial Vaccines
- Cancer Vaccines
- Allergy Vaccines
- Other Indication
- Middle East & Africa Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
- Subunit Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- Middle East & Africa Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Nasal
- Middle East & Africa Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Pediatric Age Group
- Adult Age Group
- Middle East & Africa Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
- Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Vaccine Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Vaccine Market, 2021-2033 (US$M)
MEA vaccine market statistics, by indication, 2021-2033 (US$M)
